Objective: To evaluate whether in stable angina, preference for coronary revascularization by either percutaneous coronary intervention (PCI) or coronary bypass surgery (CABG) is influenced by diabetic status and whether this has prognostic implications.
Introduction
Prevalence of diabetes in the general population is high, particularly in North America (7.9%) and in Europe (7.8%) [1] . In patients with established coronary artery disease (CAD) the prevalence of diabetes is even higher. In the Euro Heart Survey on Diabetes and the Heart 14% of patients with stable CAD had newly detected diabetes, whereas around 37% had impaired glucose regulation. Furthermore, patients with CAD and diabetes may have a worse prognosis [2, 3] .
Whether coronary revascularization in patients with diabetes has comparable benefits as in patients without diabetes is not yet clear. There is also debate whether coronary artery bypass surgery (CABG) or percutaneous coronary intervention (PCI) should be preferred in diabetes [4] [5] [6] . As a consequence, current treatment guidelines do not provide a firm treatment advise for the general diabetic CAD population, although some detailed recommendations are given for specific subgroups [7] [8] [9] [10] [11] [12] [13] [14] .
The Euro Heart Survey on Coronary Revascularization (EHS-CR) was
developed to obtain quantitative information on the adherence to guidelines and prognosis in patients undergoing coronary angiography [15] . The EHS-CR enrolled 3006 consecutive patients with stable CAD, and this wellcharacterised study population provides a unique opportunity for a Chapter 8 ___________________________________________________________________ 129 systematic analysis of the relation between patient characteristics (including diabetes), invasive treatment choices and prognosis.
Methods

Euro Heart survey of Coronary Revascularization
The EHS-CR was described in detail elsewhere [15] . Briefly, the survey was designed to screen consecutive patients undergoing invasive procedures in the catheterisation laboratory. Patients were enrolled if they had a diameter stenosis of at least 50% in at least one major epicardial coronary artery. Data were collected by dedicated data collecting officers and sent to a central database in the European Heart House (Sophia Antipolis, France) via the www, using the MacroTM software (InferMed, UK). The collected data included demographics, co-morbidity, diagnosis, and detailed information regarding diagnostic angiography and treatment modalities. Between November 1, 2001 and March 1, 2002 a total of 5767 patients were enrolled.
Treatment decisions
The EHS-CR is a descriptive study, and the survey protocol did not dictate any treatment decision. In general, physicians were encouraged to treat their patients in conformance with the most recent guidelines. In order to be informed of the physicians preferred, intended treatment, the survey included the question: "As the treating physician, which treatment option would be your first choice? " Treatment decisions in stable angina: diabetes ___________________________________________________________________
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According to the reply on this question, patients were classified with a physician's intention for medical treatment, PCI, or CABG.
Definitions
Since the EHS-CR was a survey of day-to-day clinical practice, it was avoided to require additional specific diagnostic tests. In this context, the survey protocol did not require specific measurements to verify the diagnosis of co-morbidities, including diabetes. For this study, patients with diabetes were classified as those who used oral hypoglycaemic agents, insulin or the combination. The extent of CAD was estimated by the number of diseased arteries and the number of diseased segments [15] .
Follow-up
Patients were followed for one year after the initial angiography. However, because of logistic reasons, 14 of the 130 hospitals (11%) were not able to provide long-term follow-up information. Consequently, follow-up duration was only 30 days in 8% of patients and 30-300 days in another 13%. The median follow-up duration was 356 days (interquartile range: 308-365 days). Follow-up data included all-cause mortality, cerebro-vascular accidents (CVAs), myocardial infarctions (MIs), and repeat revascularization procedures. As suggested by previous trials [13] , we studied the relation between diabetic status and intended treatment in three specific patient subgroups in more detail: patients with significant left main disease; patients with 3-vessel disease, combined with those with 2-vessel disease and a significant lesion in the proximal LAD; and patients with 2-vessel disease not involving the proximal LAD, combined with those with 1-vessel disease.
Data description and data analysis
Kaplan-Meier survival analyses, as well as univariable and multivariable Cox' proportional hazard regression were applied to study patient outcome at one-year follow-up. Since the number of outcome events was limited, in multivariable analyses we only adjusted for the EuroSCORE [16] . We report adjusted hazard ratios and corresponding 95% confidence intervals (CI).
All statistical tests were 2-sided, and significance was stated at the classical 0.05 probability level.
Treatment decisions in stable angina: diabetes ___________________________________________________________________ [10] . ¶ European System for Cardiac Operative Risk Evaluation, which is a score developed to quantify the risk of perioperative mortality in patients scheduled for cardiac surgery [16] . # Based on quantitative or qualitative measurements.
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In patients with a history of prior CABG only.
Results
Patient characteristics
A total of 3006 patients were diagnosed with stable angina. Complete data on diabetic status and intended treatment was available in 2928 (97%)
patients, who compose our study population. A total of 587 (20%) patients had diabetes.
There were important differences in clinical and angiographic baseline characteristics between patients with and without diabetes (table 1) .
Patients with diabetes were more often women, and had a higher prevalence of chronic renal insufficiency, peripheral vascular disease and cerebro-vascular disease. The size of the myocardium at risk was 
Univariable analyses
In patients with diabetes, a PCI was intended in 282 (48%) patients and CABG in 155 (26%) patients, compared to 1217 (52%) and 586 (25%) in patients without diabetes respectively. There were, however, some specific patient subgroups in which the presence of diabetes seemed to influence choice of treatment (table 2) . The presence of diabetes was associated with an increased physician's preference for medical treatment in women, in patients without heart failure, in those with mitral valve insufficiency, and in patients with 4 or more diseased segments. In contrast, diabetes was associated with an increased preference for revascularization in patients with previous PCI, and those with mild heart failure. In the diabetics, an increased physician's preference for CABG rather than PCI was observed in patients below the age of 60 years, in women, in patients with previous PCI or extensive anti-anginal medication, and in those with a Euro-SCORE <3 points. An increased physician's preference for intervention by PCI rather than CABG was observed in diabetic patients with a large area of jeopardised myocardium.
The extent of CAD was strongly associated with the physician's preference for revascularization (table 2) . Diabetes did not influence this association.
Among patients selected for revascularization, CABG was preferred in those with more extensive disease, independent of the coexistence of diabetes. 
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Multivariable analyses
After multivariable adjustment for a range of potential cofounders (table 3) , the odds ratio for the relation between diabetic status and preferred revascularization versus medical treatment was 0.91 (95% CI 0.70 to 1.17).
Thus, the treating physicians did not have a differential preference for either medical treatment or coronary revascularization in relation to diabetic status. There was also no preference for either CABG or PCI in relation to diabetic status, with the adjusted odds ratio 0.92 (95% CI 0.63 to 1.3).
However, diabetes significantly influenced treatment decisions in several subgroups according to age, previous PCI, heart-failure, concomitant valvular disease and Euro-Score. For example, the presence of diabetes was associated with an increased preference for coronary revascularization in patients with mild heart failure (NYHA class I or II). Furthermore, diabetes was associated with an increased preference for CABG rather than PCI in patients below the age of 60 years, but associated with an increased preference for PCI in elderly patients.
Outcome after one-year
The incidence of the composite endpoint of all-cause death, non-fatal CVA or non-fatal MI at one-year follow-up was 7.3% in patients with diabetes and 6.8% in patients without diabetes (adjusted hazard ratio 1.0 and 95%CI 0.7 to 1.4). Patients with more extensive disease had a higher incidence of death, CVA or MI at one-year follow-up than those with less extensive disease ( figure 1, table 3) . However, importantly, in the subgroups according to the extent of CAD there were no significant differences in the incidence of this composite endpoint between patients with and without diabetes.
Treatment decisions in stable angina: diabetes ___________________________________________________________________ * An odds ratio>1 implies that treated diabetes is associated with an increased preference for the treatment option in the corresponding column, whereas an odds ratio <1 implies that treated diabetes is associated with an increased preference for the alternative. Odds ratios are adjusted for all variables that are listed in tables 2 and 3, as appropriate. § The analysis is limited to patients with intended coronary revascularization.
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Concerning the relation between diabetic status, treatment choice and outcome, because of small numbers, patients with left main disease or 3-vessel disease were considered as one group. Regardless of the extent of the disease, patients selected for PCI had a lower incidence of major adverse cardiovascular or cerebro-vascular events at 1-year follow-up than those selected for medical treatment or CABG (table 4) , but again we observed no difference in the relation between intended treatment and outcome according to diabetic status. 
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Discussion
This analysis revealed that in stable angina subsequent treatment decisions regarding revascularization (and the choice for either CABG or PCI) were not influenced by the presence of diabetes. Importantly, diabetic patients with left main disease, proximal LAD disease, or more extensive, multivessel disease were not more likely to undergo coronary revascularization (or CABG) than their non-diabetic counterparts. Diabetes was also not associated with a poor prognosis.
Previous (1999) and current (2002) guidelines recommend CABG rather than PCI in patients with diabetes and multivessel disease [10, 11] . This treatment advise is mainly based on post-hoc analyses from randomised trials that were conducted before the use of stents and glycoprotein (GP) IIb/IIIa inhibitors. In the BARI trial, patients with treated diabetes who were randomised to CABG had significant better survival after 7-year follow-up than those randomised to balloon angioplasty [4] . To some extent, this finding was confirmed by a meta-analysis of 13 randomised trials of CABG versus balloon angioplasty (including BARI), which demonstrated improved survival in favour of CABG at 4-year follow-up, but no longer at 6.5-year follow-up [17] .
How can we understand the discrepancy between guidelines recommendations and the clinical practice patterns that we observed?
Possibly, those involved in the care of patients with stable angina are not convinced that patients with diabetes should be treated differently than those without diabetes, especially since large-scale randomised trials are lacking. The ongoing BARI 2D trial, in which diabetic patients will be randomly allocated to aggressive medical management, targeting at Treatment decisions in stable angina: diabetes ___________________________________________________________________ 142 optimal glycemic and metabolic control, or revascularization, may help to solve this 'burgeoning dilemma', as the investigators call it [18] .
Furthermore, it is well-known that patients enrolled in clinical trials form a selected population, particularly in randomised trials comparing PCI and CABG [19] . In this respect, observational studies, including the BARI registry [5] , reported similar outcome after CABG and PCI in patients with diabetes and symptomatic coronary disease [6] . Probably, antirestenotic, drug-eluting stents (DES) will improve the results of PCI relative to CABG in diabetic patients [22, 23] . The ongoing CARDia, FREEDOM and BARI 2D trials, which enrol patients with coronary disease and diabetes, who are randomised to either CABG or PCI with DES and modern antiplatelet therapy, including GP IIb/IIIa inhibitors and clopidogrel, may shed a vivid light on the PCI-versus-CABG debate.
In our survey, diabetes was not associated with an increased incidence of major adverse cardiac and cerebral events. Especially diabetic patients scheduled for PCI had similar prognosis as non-diabetics. It is true that the limited number of patients and the short duration of follow-up might have masked significant differences, but large differences in clinical outcome can 
Limitations
This study has several limitations, which need to be addressed. First, The EHS-CR was conducted mainly in hospitals with liberal access to coronary revascularization facilities. It is known that the availability of specific medical resources decreases the threshold for it's use [24] . Thus, the percentage of patients undergoing revascularization, particularly CABG, might have been relative high. However, there is no indication that this has been differently so in patients with and without diabetes.
Second, as the EHS-CR is a survey of routine clinical practice, the treating physician was not enforced to use specific laboratory tests in order to establish the diagnosis 'diabetes'. Thus, we cannot exclude the possibility that misclassification of diabetes had occurred. However, the clinical and angiographic characteristics of patients with diabetes corresponded quite well with other datasets of diabetics with stable coronary disease [25] .
Third, no Core Lab analysis was performed of the qualifying coronary angiography. Consequently, detailed anatomic information that may have influenced treatment decisions was lacking. This is especially relevant for the 366 patients with a prior history of CABG. However, sensitivity analyses that excluded these patients showed consistent results.
Conclusions
Diabetes is not among the factors that determine treatment decisions regarding revascularization in patients with stable coronary disease.
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Diabetes was not associated with a worse prognosis, independent of invasive treatment preference. In expectation of the results of ongoing clinical trials, comparing several medical and more invasive treatment strategies, guidelines for the management of CAD patients with diabetes should be updated more systematically than is currently the case.
